MTOR and medullary thyroid gland carcinoma: In particular, analysis of grade 3 and 4 AE across both WD-NEN and MTC diagnoses, showed that there is evidence of a higher risk for serious toxicities in patients receiving the mTOR inhibitor everolimus and different TKIs and involved more commonly cardiovascular disorders for these agents, as compared to SSAs and telotristat etiprate.